

# Vladimir M Moiseyenko

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9482999/publications.pdf>

Version: 2024-02-01

50  
papers

8,506  
citations

218677

26  
h-index

206112

48  
g-index

50  
all docs

50  
docs citations

50  
times ranked

7919  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group. <i>Journal of Clinical Oncology</i> , 2006, 24, 4991-4997.	1.6	1,772
2	Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. <i>Journal of Clinical Oncology</i> , 2012, 30, 3499-3506.	1.6	1,214
3	Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results. <i>Journal of Clinical Oncology</i> , 2002, 20, 2812-2823.	1.6	1,034
4	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 490-499.	10.7	740
5	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1547-1553.	1.6	498
6	Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 59-68.	10.7	446
7	An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. <i>Lancet</i> , The, 2008, 372, 145-154.	13.7	312
8	Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. <i>Annals of Oncology</i> , 2001, 12, 1247-1254.	1.2	284
9	Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 3205-3209.	1.6	237
10	Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM – Anti-CD3 Antibody: A Phase I/II Study. <i>Clinical Cancer Research</i> , 2007, 13, 3899-3905.	7.0	226
11	Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5660-5667.	1.6	211
12	Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR trial. <i>European Journal of Cancer</i> , 2014, 50, 320-331.	2.8	211
13	Randomised, phase II trial comparing oral capecitabine (Xeloda®) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. <i>British Journal of Cancer</i> , 2002, 86, 1367-1372.	6.4	180
14	Quality of Life With Docetaxel Plus Cisplatin and Fluorouracil Compared With Cisplatin and Fluorouracil From a Phase III Trial for Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group. <i>Journal of Clinical Oncology</i> , 2007, 25, 3210-3216.	1.6	164
15	A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. <i>Annals of Oncology</i> , 2010, 21, 1810-1816.	1.2	114
16	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. <i>European Journal of Cancer</i> , 2013, 49, 3616-3624.	2.8	78
17	The role of breast self-examination in early breast cancer detection (results of the 5-years USSR/WHO) Tj ETQq1 1 0,784314 rgBT /Over 5,7 67		
18	Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Recombinant Human Intestinal Trefoil Factor Oral Spray for Prevention of Oral Mucositis in Patients With Colorectal Cancer Who Are Receiving Fluorouracil-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 4333-4338.	1.6	58

#	ARTICLE	IF	CITATIONS
19	Survival Benefit with Capecitabine/Docetaxel Versus Docetaxel Alone: Analysis of Therapy in a Randomized Phase III Trial. <i>Clinical Breast Cancer</i> , 2004, 5, 273-278.	2.4	54
20	Quality of Life in the Trastuzumab for Gastric Cancer Trial. <i>Oncologist</i> , 2014, 19, 712-719.	3.7	50
21	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , 2016, 21, 292-300.	3.7	40
22	Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. <i>Targeted Oncology</i> , 2016, 11, 383-400.	3.6	40
23	High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Onkologie</i> , 2010, 33, 231-238.	0.8	39
24	Drug therapy for hereditary cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2011, 9, 5.	1.5	35
25	Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. <i>Journal of Geriatric Oncology</i> , 2018, 9, 32-39.	1.0	32
26	Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. <i>Supportive Care in Cancer</i> , 2012, 20, 1471-1478.	2.2	27
27	Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. <i>Medical Oncology</i> , 2013, 30, 545.	2.5	26
28	Phase II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma. <i>British Journal of Cancer</i> , 2013, 109, 1451-1459.	6.4	25
29	Phase I/II trial of gene therapy with autologous tumor cells modified with tag7/PGRP-S gene in patients with disseminated solid tumors. <i>Annals of Oncology</i> , 2005, 16, 162-168.	1.2	24
30	KIT mutations in Russian patients with mucosal melanoma. <i>Melanoma Research</i> , 2011, 21, 555-559.	1.2	23
31	Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 145-153.	2.6	23
32	Molecular-based choice of cancer therapy: Realities and expectations. <i>Clinica Chimica Acta</i> , 2007, 379, 1-13.	1.1	22
33	Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. <i>European Journal of Cancer</i> , 2015, 51, 18-26.	2.8	21
34	A Phase III Study of Balgrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. <i>Oncologist</i> , 2016, 21, 7-15.	3.7	21
35	Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. <i>Medical Oncology</i> , 2014, 31, 199.	2.5	20
36	High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 91-94.	1.0	18

#	ARTICLE	IF	CITATIONS
37	EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: A case report. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 548-550.	1.6	17
38	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 109-117.	1.3	15
39	Clinical trials on adjuvant chemotherapy for breast cancer. <i>Cancer</i> , 1986, 57, 1957-1960.	4.1	14
40	High-dose toremifene in advanced renal-cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 547-551.	2.3	12
41	Measurement of DPD and TS Transcripts Aimed to Predict Clinical Benefit from Fluoropyrimidines: Confirmation of the Trend in Russian Colorectal Cancer Series and Caution Regarding the Gene Referees. <i>Oncology Research and Treatment</i> , 2007, 30, 295-300.	1.2	11
42	Phase II dose-finding study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy. <i>Medical Oncology</i> , 2015, 32, 623.	2.5	11
43	Down-Staging of EGFR Mutation-Positive Advanced Lung Carcinoma with Gefitinib Followed by Surgical Intervention: Follow-Up of Two Cases. <i>Onkologie</i> , 2009, 32, 674-677.	0.8	8
44	High efficacy of cisplatin neoadjuvant therapy in a prospective series of patients carrying BRCA1 germ-line mutation. <i>Medical Oncology</i> , 2015, 32, 89.	2.5	8
45	EGFR T790M Mutation in TKI-Naïve Clinical Samples: Frequency, Tissue Mosaicism, Predictive Value and Awareness on Artifacts. <i>Oncology Research and Treatment</i> , 2018, 41, 634-642.	1.2	8
46	Cell Technologies in Immunotherapy of Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2007, 601, 387-393.	1.6	8
47	Current evaluation of the contribution of self-examination to secondary prevention of breast cancer. <i>European Journal of Epidemiology</i> , 1987, 3, 78-83.	5.7	4
48	Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?. <i>Onkologie</i> , 2011, 34, 559-560.	0.8	3
49	Antitumor efficacy of an isolated hind leg perfusion with a pH-increased solution in the Plissâ€™ lymphosarcoma graft rat model. <i>AlĚmanah KliniĚskoj Mediciny</i> , 2021, 49, 541-549.	0.3	1
50	The individualization of treatment based on molecular markers. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 251-252.	0.5	0